Our board of directors recognizes that one of its key responsibilities is to ensure that Lilly is governed in a manner that provides both independent oversight as well as efficient and effective decision-making. Some of the ways the board accomplishes this is through implementing the principles of good corporate governance and strong membership on our board that reflects a diverse range of backgrounds, ages, experiences and tenures. We believe the composition of our board provides an effective balance of historical perspective and an understanding of the evolution of our business with fresh perspectives and insights.
The company's 15 directors range in age from 48 to 71 and include six women and seven members of underrepresented groups, including minority group members as well as lesbian, gay, bisexual, transgender or queer (LGBTQ) individuals. Our directors bring to the Lilly board experiences from an array of geographies and industries, including finance, health care, tech and academia. Also on our executive committee, which includes our CEO, seven of 15 members are women (approximately 47%), including one who is a minority group member.
In early 2021, the board added two new members – Gabrielle Sulzberger and Kimberly H. Johnson. Learn more about them below.
Get to Know a New Board Member: Gabrielle Sulzberger
Get to Know a New Board Member: Kimberly H. Johnson
Lilly Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. The company’s operations, results, business, goals and strategy may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes or developments in laws and regulations, including health care reform.
For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.
Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations.